Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not cost-effective at current net prices. Efforts to reduce the net prices of new antiobesity medications are essential to ensure equitable access to highly effective antiobesity medications.
Authors
- Neda Laiteerapong (ORCID: https://orcid.org/0000-0003-0124-4325)
- Elbert S. Huang (ORCID: https://orcid.org/0000-0002-4628-2061)
- David D. Kim (ORCID: https://orcid.org/0000-0002-3383-8972)
- Jennifer H. Hwang
Institutions
- Chicago Department of Public Health (US)
- University of Chicago (US)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1001/jamahealthforum.2024.5586
- Citations
- 41
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 57.17